News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN)'s Diabetes Drug Xigduo Approved In Europe


1/22/2014 7:23:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca said European regulators had approved Xigduo for type 2 diabetes, in what was the first green light for a fixed dose combination of a SGLT2 inhibitor and metformin. The drug combines in a twice daily tablet Forxiga, a SGLT2 inhibitor that reduces the reabsorption of excess glucose, and metformin, a standard in treating the condition.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Market Watch
Read at Wall Street Journal
Read at RTT News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES